Washington Oregon Biotech Networks’ Post

The first seed company from Cure Ventures, a Boston biotech venture capital firm that launched last year, is now raising more than $70 million, according to a new filing.

⚡️ Foresite Capital raises $900M sixth fund for investing in life sciences companies 🎥 Venture fundraising has been a slog over the last few years, even for firms with a strong track record. That’s Foresite Capital’s experience. Despite having 47 IPOs, 28 M&As and 58 FDA-approved drugs under its belt, the 13-year-old multi-stage healthcare and life sciences firm took two years to raise its sixth fund. 🎥 The San Francisco-based firm was set on making sure its sixth vehicle wasn’t significantly smaller than its fifth fund, which totaled $969 million, consisting of a $775 million core fund and a $194 million companion opportunities fund. Foresite hired Hadi Tabbaa to bridge the funding gap and lead the firm’s widespread investment relations effort. Tabbaa, previously with B Capital and Coatue Management, has helped the firm bring in new LPs, including family offices from Asia and the Middle East. 🎥 The firm began investing from fund six nearly two years ago and backed a number of interesting companies over that period. Foresite Capital made a big splash in April when its accelerator, Foresite Labs, along with ARCH Venture Partners, invested $1 billion to incubate Xaira, a new AI drug discovery startup. 🕰 Tananbaum also highlighted the firm’s recent participation in the $135 million Series A of Latigo Bio, a clinical-stage biotech company testing a non-opioid pain treatment.

In today's fast-paced venture capital landscape, the focus often leans towards rapid market entry over groundbreaking technical innovation. This shift can sideline transformative deep tech ventures that require longer development timelines and holistic investment strategies. At Aventurine Capital Group, we are committed to revitalizing the spirit of mid-20th-century venture investing by prioritizing foundational intellectual property and incubating startups in robotics, AI, quantum computing, life sciences, secure systems, and energy. Our dual emphasis on deep tech IP and venture development aims to foster the commercialization of technologies poised to revolutionize the U.S. economy. While traditional venture capital remains vital, our approach introduces a complementary investment style tailored for early-stage deep tech innovation. https://lnkd.in/gyzbhN-B #DeepTech #Innovation #Startups #VC #IP #Patents

Traditional venture capital is often constrained by short return windows, limiting its ability to fund truly transformative, deep tech innovations. Aventurine Capital Group is reviving the spirit of mid-20th century venture investing by focusing on foundational technologies with the potential to revolutionize multiple markets, from AI to quantum computing. By incubating startups and developing IP across various sectors, Aventurine aims to drive long-term growth and address future challenges. This holistic approach seeks to complement the current VC model, fostering the commercialization of world-changing technologies. https://lnkd.in/gyzbhN-B #VC #IP #Patents #StartUps #DeepTech

Scientifica Venture Capital unveiled a new $200 million fund #Scientifica Venture Capital has unveiled a €200 million fund, Scientifica Fund 1 (SF1), to empower startups and projects in future computing, smart materials, advanced industries, and environmental technologies. Led by Managing Partner Riccardo D’Alessandri and General Partner Patrick Leoni Sceti, the fund will focus on removing economic barriers to innovation through a Zero CapEx investment model. This approach provides young companies with access to advanced technological resources, including proprietary and certified laboratories across Italy, without upfront costs for equipment or facilities. Scientifica's mission is to bridge the gap between science and venture capital by supporting companies from ideation to scale-up, optimizing their time to market and reducing risks. The fund is part of a broader initiative involving over 100 professionals and a growing network of research infrastructures. Notable upcoming projects include Quantum Italia, a vertical fund focused on technology transfer in frontier technologies. With headquarters in Rome and L’Aquila, Scientifica is scaling its global presence. It has established a strategic hub in Silicon Valley, led by Jon Lunetta, to connect European startups—particularly those in AI—to the U.S. tech ecosystem. Additionally, a partnership in France is advancing quantum technologies, solidifying its leadership in Europe and beyond. The article on #VCwiretech in the first comment.

Venture capital funding is becoming harder to secure for startup companies. But still, plenty of Triangle companies scored big in the past year. #venturecapital #funding #startups #investors #investing #raleigh #durham #northcarolina

GVC Gaesco has joined with Next Tier Ventures to establish a new €50 million fund aimed at supporting startups specialising in AI. The investment vehicle will be named Next Tier GVC Gaesco S.C.R.S.A 🇩🇪 🤖 This collaboration will focus on targeting 30–35 operations in B2B AI startups across Europe, the United States, and Latin America. The fund will focus on identifying projects where AI technologies enhance industries and improve lives, with a strategy rooted in selection, active involvement, and tailored divestment plans. Paco Illueca, Investment Director of GVC Gaesco, expressed enthusiasm for the initiative: “Our partnership with Next Tier Ventures stands for a further step in GVC Gaesco’s commitment to venture capital, thereby completing our range of investment products and meeting the growing demands from our customers. The birth of this first AI – focused investment fund is only the very first of many to be released as a result of our collaboration with Next Tier Ventures.” https://lnkd.in/dCzDFMuc

This Weeks 10 Biggest Funding Rounds (via @Crunchbase) 👍 This week witnessed another surge of substantial funding rounds, notably led by the biotech sector, with three startups securing positions in the top five. March appears to be continuing the trend set by February, with #investors demonstrating a growing willingness to invest significant sums in promising ventures. Read more: https://loom.ly/_eQ7M28 #vc #venturecapital #venturefunding #funding

𝐁𝐢𝐠 𝐍𝐞𝐰𝐬 𝐟𝐫𝐨𝐦 𝐀𝐭𝐥𝐚𝐬 𝐕𝐞𝐧𝐭𝐮𝐫𝐞: $𝟒𝟓𝟎𝐌 𝐅𝐮𝐧𝐝 𝐗𝐈𝐕 𝐂𝐥𝐨𝐬𝐞𝐝! Atlas Venture has announced the closing of Fund XIV, a $450M investment vehicle dedicated to early-stage biotech innovation. This new fund reinforces their commitment to the science-first, seed-led venture creation model, which has driven their success in launching transformative therapies. ✨ 𝐊𝐞𝐲 𝐡𝐢𝐠𝐡𝐥𝐢𝐠𝐡𝐭𝐬 𝐟𝐫𝐨𝐦 𝐀𝐭𝐥𝐚𝐬’ 𝐚𝐧𝐧𝐨𝐮𝐧𝐜𝐞𝐦𝐞𝐧𝐭: ✅ Fund XIV follows a streak of notable portfolio successes, including acquisitions (Nimbus Tyk2, Versanis, Aiolos, Mariana) and IPOs (Disc, Korro, Q32, Third Harmonic). ✅ Over the past two years, Atlas has launched 16 new companies and recruited talented executives to lead their ventures. ✅ The firm continues to prioritize a disciplined, focused approach, resisting the industry trend of scaling fund sizes for growth's sake. An interesting shift comes with the transition of JF Formela, one of Atlas’ long-time leaders, who will no longer make new investments but will stay actively involved with their legacy portfolio. His impact on the biotech venture field over decades has been immense, spanning innovations from combinatorial chemistry to CRISPR. 𝐖𝐡𝐲 𝐤𝐞𝐞𝐩 𝐭𝐡𝐞 𝐟𝐮𝐧𝐝 𝐚𝐭 $𝟒𝟓𝟎𝐌? Atlas’ decision reflects their focus on long-term value creation while addressing the “venture capital math problem”: In early-stage biotech, a few big winners drive the majority of returns. For a $450M fund, "just" five companies need to collectively generate over $1.1B in returns—already a high bar. Larger funds multiply this challenge, requiring massive exits that are far less common in biotech. By staying disciplined, Atlas is prioritizing quality over quantity, ensuring they can continue delivering meaningful results without chasing unrealistic outcomes. This milestone underscores Atlas’ leadership in biotech venture creation. It’s exciting to see how Fund XIV will contribute to the next wave of groundbreaking medicines. 💊 💡 What are your thoughts on their disciplined approach in a market increasingly dominated by scaling funds?

Denmark’s first deep tech venture fund, PSV Hafnium, closes €38.1M investment round PSV Hafnium, a Danish venture fund, has secured €38,1 million (DKK 285 millio0n) in commitments from the European Investment Fund (EIF) and the Export and Investment Fund of Denmark (EIFO). With a total fund size cap of €80,4 million (DKK 600 million), it aims to invest in around 30 early-stage deep tech startups across Denmark and the Nordics. The fund focuses on science-based clean tech, health tech, and next-generation industrial solutions, aligning with climate action and environmental sustainability goals. Leveraging close ties with the DTU - Technical University of Denmark PSV Hafnium supports startups from pre-seed to seed stage, offering patient capital and expertise to commercialize cutting-edge research. https://lnkd.in/dNRGrhRd #funding #nordicmade #denmark #startups #deeptech #venturecapital #trending